Zhao Wu

InstitutionPeking University First Hospital
AddressBeijing
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 7 Covid-19 publications, with a maximum of 2 publications in June 2020
    All Publications
    Bar chart showing 73 publications over 14 distinct years, with a maximum of 14 publications in 2018
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhao H, Zhang C, Zhu Q, Chen X, Chen G, Sun W, Xiao Z, Du W, Yao J, Li G, Ji Y, Li N, Jiang Y, Wang Y, Zeng Q, Li W, Gong B, Chang X, Zhu F, Jiang X, Li J, Wu Z, Liu Y, Peng P, Wang G. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. Int Immunopharmacol. 2021 Aug; 97:107702. PMID: 33930706.
      Citations: 4     Fields:    Translation:HumansCells
    2. Zhang C, Mu J, Zhang D, Li J, Wang H, Jin Y, Han Y, Li H, Zhang C, Yu P, Guo R, Dou X, Chu Y, Wu Z, Dong X, Wang G, Zhao H. Diverse clinical processes of 16 COVID-19 cases who concentrated infection in the same workplace in Beijing, China: An observational study. Medicine (Baltimore). 2020 Dec 24; 99(52):e23800. PMID: 33350766.
      Citations:    Fields:    Translation:HumansPHPublic Health
    3. Zhang C, Wu Z, Li JW, Tan K, Yang W, Zhao H, Wang GQ. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol. 2021 03; 93(3):1378-1386. PMID: 33107641.
      Citations: 14     Fields:    Translation:HumansCells
    4. Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, Wang K, Yu J, Wu Z, Chen X, Wang G. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother. 2021 Jan; 133:110825. PMID: 33378989.
      Citations: 17     Fields:    Translation:Humans
    5. Zhang C, Li J, Wu Z, Wang H, Que C, Zhao H, Wang G. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 08; 21(1):495. PMID: 32513299.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    6. Li J, Zhang C, Wu Z, Wang G, Zhao H. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 05; 21(1):488. PMID: 32503657.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    7. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020 May; 55(5):105954. PMID: 32234467.
      Citations: 647     Fields:    Translation:HumansCellsPHPublic Health